Adrenomedullin Antagonist Nanoparticles Inhibit Breast Cancer Brain Metastasis by Immunomodulating Monocytes/Macrophages

Breast cancer brain metastasis (BCBM) is a devastating disease with limited treatment options, largely due to the presence of the blood-brain barrier (BBB) in the central nervous system (CNS), and thus, the development of effective alternative therapies for BCBM remains a significant unmet clinical challenge. Herein, we found that monocytes, M2 macrophages, and adrenomedullin (AM) were abundantly present in human BCBM. Therefore, we innovatively proposed monocytes/macrophages as promising immunomodulatory targets for effective immunotherapy of BCBM in mice models. The high-density lipoprotein-mimicking peptide-phospholipid scaffold (HPPS) nanoparticle efficiently targets monocytes/macrophages. Meanwhile, the adrenomedullin antagonist (AMA)-carrying HPPS (AMA-HPPS) nanoparticle has the potential to target and immunomodulate monocytes/macrophages into antitumor effector cells due to the pro-inflammatory polarization ability of AMA. Given this, AMA-HPPS effectively targeted and modulated circulating monocytes after intravenous injection, enabling the delivery of nanoparticle to brain metastasis sites. Incorporating immunomodulatory CpG into AMA-HPPS (forming AMA-HPPS-CpG) further enhanced monocyte targeting and immunomodulation. Thus, AMA-HPPS-CpG further inhibited the BCBM and prolonged the survival of mice by modulating the differentiation of infiltrating monocytes/macrophages into M1 macrophages and promoting the infiltration of CD8<sup>+</sup> T cells into the brain. This effect was attributed to the activation of the NF-κB pathway in monocytes/macrophages following the uptake of nanoparticles, which reprogrammed the immunosuppressive tumor microenvironment. Therefore, this study highlights a promising immunotherapy strategy for brain metastasis by AMA-HPPS nanodrugs eliciting the pro-inflammatory polarization of monocytes/macrophages that have infiltrated the CNS as effector cells rather than considering monocytes/macrophages merely as a drug delivery system across the BBB.

Authors

Institutions

Publication Details

Journal
ACS Nano
Published
2026-03-17
DOI
https://doi.org/10.1021/acsnano.5c15040
Primary Topic
Cancer, Stress, Anesthesia, and Immune Response
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adrenomedullin Antagonist Nanoparticles Inhibit Breast Cancer Brain Metastasis by Immunomodulating Monocytes/Macrophages

Xingxing Yu, J Chen, Yi Zhao, Zhihong Zhang et al.
ACS Nano
Cancer, Stress, Anesthesia, and Immune Response
article

Adrenomedullin Antagonist Nanoparticles Inhibit Breast Cancer Brain Metastasis by Immunomodulating Monocytes/Macrophages

Xingxing Yu, J Chen, Yi Zhao, Zhihong Zhang, Yanfeng Dai, Xuenan Yuan, Gehao Chen, Y. Q. Liu, Wei J. Wang, Yu Shi, Mianfu Cao
article en

Abstract

Breast cancer brain metastasis (BCBM) is a devastating disease with limited treatment options, largely due to the presence of the blood-brain barrier (BBB) in the central nervous system (CNS), and thus, the development of effective alternative therapies for BCBM remains a significant unmet clinical challenge. Herein, we found that monocytes, M2 macrophages, and adrenomedullin (AM) were abundantly present in human BCBM. Therefore, we innovatively proposed monocytes/macrophages as promising immunomodulatory targets for effective immunotherapy of BCBM in mice models. The high-density lipoprotein-mimicking peptide-phospholipid scaffold (HPPS) nanoparticle efficiently targets monocytes/macrophages. Meanwhile, the adrenomedullin antagonist (AMA)-carrying HPPS (AMA-HPPS) nanoparticle has the potential to target and immunomodulate monocytes/macrophages into antitumor effector cells due to the pro-inflammatory polarization ability of AMA. Given this, AMA-HPPS effectively targeted and modulated circulating monocytes after intravenous injection, enabling the delivery of nanoparticle to brain metastasis sites. Incorporating immunomodulatory CpG into AMA-HPPS (forming AMA-HPPS-CpG) further enhanced monocyte targeting and immunomodulation. Thus, AMA-HPPS-CpG further inhibited the BCBM and prolonged the survival of mice by modulating the differentiation of infiltrating monocytes/macrophages into M1 macrophages and promoting the infiltration of CD8<sup>+</sup> T cells into the brain. This effect was attributed to the activation of the NF-κB pathway in monocytes/macrophages following the uptake of nanoparticles, which reprogrammed the immunosuppressive tumor microenvironment. Therefore, this study highlights a promising immunotherapy strategy for brain metastasis by AMA-HPPS nanodrugs eliciting the pro-inflammatory polarization of monocytes/macrophages that have infiltrated the CNS as effector cells rather than considering monocytes/macrophages merely as a drug delivery system across the BBB.

ACS Nano
University Health Network (CA), Army Medical University (CN), Hainan University (CN), Princess Margaret Cancer Centre (CA), Yangon University of Economics (MM), Applied Photonics (United Kingdom) (GB), Wuhan National Laboratory for Optoelectronics (CN), Health & Life (Taiwan) (TW), Huazhong University of Science and Technology (CN)
Good health and well-being
Openalex Percentile: Top 28%
Cancer, Stress, Anesthesia, and Immune Response
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.